Soleno Therapeutics, Inc. Board of Directors

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Dr. Anish Bhatnagar M.D.

Dr. Anish Bhatnagar M.D.

President, CEO, COO & Director

Ms. Meredith Manning M.B.A.

Ms. Meredith Manning M.B.A.

Chief Commercial Officer

Ms. Kristen Yen M.S.

Ms. Kristen Yen M.S.

Senior Vice President of Clinical Operations

Dr. Michael Huang M.D.

Dr. Michael Huang M.D.

Senior Vice President of Clinical Development

Mr. James H. MacKaness

Mr. James H. MacKaness

Chief Financial Officer

Dr. Neil M. Cowen M.B.A., Ph.D.

Dr. Neil M. Cowen M.B.A., Ph.D.

Senior Vice President of Drug Development

Ms. Patricia C. Hirano M.P.H.

Ms. Patricia C. Hirano M.P.H.

Senior Vice President of Regulatory Affairs

Ms. Lauren Budesheim

Ms. Lauren Budesheim

Vice President of People

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.